参考文献/References:
[1] 中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志,2020,35(9):833-854.
[2] Scalone G,Niccoli G,Refaat H,et al. Not all plaque ruptures are born equal:an optical coherence tomography study[J]. Eur Heart J Cardiovasc Imaging,2017,18(11):1271-1277.
[3] Lawler PR,Bhatt DL,Godoy LC,et al. Targeting cardiovascular inflammation:next steps in clinical translation[J]. Eur Heart J,2021,42(1):113-131.
[4] Yuan X,Bhat OM,Meng N,et al. Protective role of autophagy in Nlrp3 inflammasome activation and medial thickening of mouse coronary arteries[J]. Am J Pathol,2018,188(12):2948-2959.
[5] Wang R,Wang Y,Mu N,et al. Activation of NLRP3 inflammasomes contributes to hyperhomocysteinemia-aggravated inflammation and atherosclerosis in apoE-deficient mice[J]. Lab Invest,2017,97(8):922-934.
[6] Ridker PM,Everett BM,Thuren T,et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med,2017,377(12):1119-1131.
[7] Gomez D,Baylis RA,Durgin BG,et al. Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice[J]. Nat Med,2018,24(9):1418-1429.
[8] Robinson PC,Terkeltaub R,Pillinger MH,et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease[J]. Am J Med,2022,135(1):32-38.
[9] Nidorf SM,Eikelboom JW,Budgeon CA,et al. Low-dose colchicine for secondary prevention of cardiovascular disease[J]. J Am Coll Cardiol,2013,61(4):404-410.
[10] Tardif JC,Kouz S,Waters DD,et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med,2019,381(26):2497-2505.
[11] Nidorf SM,Fiolet ATL,Mosterd A,et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med,2020,383(19):1838-1847.
[12] Chen Y,Zhang H,Chen Y,et al. Colchicine may become a new cornerstone therapy for coronary artery disease:a meta-analysis of randomized controlled trials[J]. Clin R heumatol,2022,41(6):1873-1887.
[13] Andreis A,Imazio M,Casula M,et al. Colchicine efficacy and safety for the treatment of cardiovascular diseases [J]. Intern Emerg Med,2021,16(6):1691-1700.
[14] Samuel M,Tardif JC,Khairy P,et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial(COLCOT)[J]. Eur Heart J Qual Care Clin Outcomes,2021,7(5):486-495.
[15] Protogerou AD,Zampeli E,Fragiadaki K,et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis[J]. Atherosclerosis,2011,219(2):734-736.
[16] McInnes IB,Thompson L,Giles JT,et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis:MEASURE,a randomised,placebo-controlled study[J]. Ann Rheum Dis,2015,74(4):694-702.
[17] Choi IA,Sagawa A,Lee EY,et al. Tocilizumab increases body weight and serum adipokine levels in patients with rheumatoid arthritis independently of their treatment response:a retrospective cohort study[J]. J Korean Med Sci,2020,35(22):e155.
[18] Ridker PM,Devalaraja M,Baeres FMM,et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk(RESCUE):a double-blind,randomised,placebo-controlled,phase 2 trial[J]. Lancet,2021,397(10289):2060-2069.
[19] Baoqi Y,Dan M,Xingxing Z,et al. Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis[J]. Front Cardiovasc Med,2022,8:812631.
[20] Mangoni AA,Zinellu A,Sotgia S,et al. Methotrexate and cardiovascular protection:current evidence and future directions[J]. Clin Med Insights Ther,2017,9:1179559X17741289.
[21] Ridker PM,Everett BM,Pradhan A,et al. Low-dose methotrexate for the prevention of atherosclerotic events[J]. N Engl J Med,2019,380(8):752-762.
[22] Ulander L,Tolppanen H,Hartman O,et al. Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction:the randomized,double-blind,placebo-controlled OXI pilot trial[J]. Int J Cardiol,2021,337:21-27.
[23] Bally M,Beauchamp ME,Abrahamowicz M,et al. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure[J]. Pharmacoepidemiol Drug Saf,2018,27(1):69-77.
[24] Kang DO,An H,Park GU,et al. Cardiovascular and bleeding risks associated with nonsteroidal anti-inflammatory drugs after myocardial infarction[J]. J Am Coll Cardiol,2020,76(5):518-529.
[25] White HD,Held C,Stewart R,et al. Darapladib for preventing ischemic events in stable coronary heart disease[J]. N Engl J Med,2014,370(18):1702-1711.
[26] Wallentin L,Held C,Armstrong PW,et al. Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease[J]. J Am Heart Assoc,2016,5(6):e003407.
[27] Siddiqui MK,Smith G,St Jean P,et al. Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events[J]. Diabetologia,2022,65(1):101-112.
[28] Riccioni G,B?ck M. Leukotrienes as modifiers of preclinical atherosclerosis?[J]. ScientificWorldJournal,2012,2012:490968.
[29] Ridker PM,Luscher TF. Anti-inflammatory therapies for cardiovascular disease[J]. Eur Heart J,2014,35(27):1782-1791.
[30] Gaztanaga J,Farkouh M,Rudd JH,et al. A phase 2 randomized,double-blind,placebo-controlled study of the effect of VIA-2291,a 5-lipoxygenase inhibitor,on vascular inflammation in patients after an acute coronary syndrome[J]. Atherosclerosis,2015,240(1):53-60.
[31] Almeida SO,Ram RJ,Kinninger A,et al. Effect of 5-lipoxygenase inhibitor,VIA-2291(Atreleuton),on epicardial fat volume in patients with recent acute coronary syndrome[J]. J C ardiovasc C omput T omogr,2020,14(4):343-348.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(7):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(7):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(7):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(7):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(7):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(7):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(7):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(7):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]